Courageous Science, Compassion for Patients
Apellis Pharmaceuticals (apellis.com) scores 79 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 67th percentile of 15242 Healthcare brands.
Apellis Pharmaceuticals is a global biopharmaceutical company founded in 2008 and headquartered in Crestwood, United States. It specializes in developing targeted C3 therapies aimed at treating diseases caused by excessive activation of the complement cascade. The company's work spans hematology, ophthalmology, and nephrology, addressing rare and debilitating conditions such as geographic atrophy. Apellis positions itself as a pioneer in complement-targeted treatment, emphasizing innovation and patient advocacy in its approach to drug development.
| Brand Name | Apellis Pharmaceuticals |
|---|---|
| Domain | apellis.com |
| Industry | Healthcare |
| Founded | 2008 |
| Headquarters | Crestwood |
| Main Competitors | Alexion Pharmaceuticals (87/100), Genentech (Roche) (84/100), Novartis (71/100), Regeneron Pharmaceuticals (92/100), Astellas Pharma (Iveric Bio) (90/100), Ionis Pharmaceuticals |
Moz Domain Authority 47/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #580,334 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive acti…" (Meta description: 37 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Apellis Pharmaceuticals?", Claude could identify the brand as of October 2026. Apellis Pharmaceuticals is a biopharmaceutical company focused on developing therapies that target the complement system, a part of the immune system implicated in many serious diseases. Its key products include pegcetacoplan, marketed as Empaveli/Aspaveli for blood disorders lik Best known for Developing complement inhibitor drugs, especially Syfovre for geographic atrophy and Empaveli for PNH.
When asked "Best brands similar to Apellis Pharmaceuticals?", Claude would recommend Apellis Pharmaceuticals as of October 2026. It's a notable name in complement-targeted therapies and a leader in treating geographic atrophy, so it would come up in discussions of similar specialty biopharma companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Apellis Pharmaceuticals's main competitors in Healthcare: Alexion Pharmaceuticals (87/100), Genentech (Roche) (84/100), Novartis (71/100), Regeneron Pharmaceuticals (92/100), Astellas Pharma (Iveric Bio) (90/100).
Sources: Brand Analyzer scan
Apellis Pharmaceuticals has limited AI-search visibility, scoring 37/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 40, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Apellis Pharmaceuticals was founded in 2008. Apellis Pharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Apellis Pharmaceuticals is headquartered in Crestwood. Apellis Pharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Apellis Pharmaceuticals scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Apellis Pharmaceuticals is a global biopharmaceutical company founded in 2008 and headquartered in Crestwood, United States. It focuses on developing targeted therapies for diseases driven by excessive activation of the complement cascade, a part of the immune system. The company operates primarily in the fields of hematology, ophthalmology, and nephrology, working to bring new treatment options to patients with rare and debilitating conditions.
Apellis Pharmaceuticals develops targeted C3 therapies designed to treat diseases caused by excessive activation of the complement cascade. Its research and development efforts are concentrated in three therapeutic areas: hematology, ophthalmology, and nephrology. The company works to bring these therapies from development through approval, aiming to provide treatment options for conditions where few previously existed, such as geographic atrophy.
Apellis Pharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Apellis Pharmaceuticals is known for pioneering targeted C3 therapies that address diseases driven by excessive complement cascade activation. The company has achieved multiple drug approvals in this space, positioning it as a leader in complement-targeted treatment development, particularly for conditions in ophthalmology, hematology, and nephrology, including geographic atrophy.
Apellis Pharmaceuticals' therapies are used by patients suffering from rare and debilitating diseases driven by complement cascade activation, including conditions in hematology, ophthalmology, and nephrology such as geographic atrophy. Healthcare providers who treat these patient populations also engage with Apellis as prescribers and clinical partners in administering the company's targeted C3 therapies.
Apellis Pharmaceuticals scores 37/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Apellis Pharmaceuticals has a weak AI-visibility profile at 37/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #580,334 (Tranco) and a Moz Domain Authority of 47/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Apellis Pharmaceuticals from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Apellis Pharmaceuticals: Anvayaa (79/100), ANCO Insurance (79/100), Аптека online (79/100), World Health Expo (WHX) Dubai - Formerly Arab Health (79/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.